CClinicalTrials.gg
CompletedNCT03499574Updated Oct 29, 2020

Feasibility Study of Biofeedback in Dysphagia Therapy Post Stroke

An interventional study of Dysphagia therapy using surface EMG as biofeedback and Usual Care in Stroke, Acute and Dysphagia, Oropharyngeal, sponsored by University of Nottingham. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-29.

Sponsored by University of Nottingham · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will investigate the feasibility of delivering swallowing therapy using surface electromyography as a means of biofeedback to patients with dysphagia in the acute stroke setting. It will investigate trends in efficacy by comparing biofeedback therapy to usual care. The results will inform future dosing and efficacy studies.

02

Conditions studied

  • Stroke, Acute
  • Dysphagia, Oropharyngeal
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • New diagnosis stroke, new dysphagia, medically stable, adequate trunk strength for videofluoroscopy.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment, previous dysphagia, previous neurological condition, severe visual impairment
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Biofeedback group

    Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.

    Behavioral: Dysphagia therapy using surface EMG as biofeedback · Behavioral: Usual Care

  • Other
    Control group

    This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education

    Behavioral: Usual Care

Interventions

  • BehavioralDysphagia therapy using surface EMG as biofeedback

    10 x 45 minute sessions over 14 days

    Also known as: Biofeedback

  • BehavioralUsual Care

    Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.

05

What researchers measure

Primary outcomes

  1. Number of participants recruited

    Count of number of participants can be recruited

    Time frame: 2 weeks

  2. Number of participants completing the treatment

    Count of number of participants completing the treatment

    Time frame: 2 weeks

  3. Average number of sessions completed

    Average number of sessions completed across participants.

    Time frame: 2 weeks

Secondary outcomes

  1. Change in Swallow function - severity

    Using Dysphagia Severity Rating Scale - scale of 0-16. 0 is normal, 16 is the most severe.

    Time frame: Pre and post 3 week intervention intervention and at 90 days

  2. Change in Swallow function - intake

    Functional Oral Intake Scale - 7 point scale from 1-7. Higher number indicated increased amount and normality of oral intake.

    Time frame: Pre and post 3 week intervention intervention and at 90 days

  3. Change in Swallow physiology - PAS

    Videofluoroscopy assessment to measure swallow safety with regards to penetration/aspiration using the Penetration Aspiration Scale (PAS). 8 point scale. The higher the number the increase in penetration/aspiration.

    Time frame: Pre and post 2 week intervention

  4. Change in swallow physiology - timing

    Videofluoroscopy assessment to measure timing of swallow physiology

    Time frame: Pre and post 2 week intervention

  5. Quality of life

    Dysphagia Handicap Index

    Time frame: Pre and post 2 week intervention and at 90 days

  6. Change in Clinical outcomes - disability

    Disability - using the Modified Rankin scale. Scale from 0-6 with higher numbers signifying increased disability

    Time frame: Pre and post 2 week intervention and at 90 days.

  7. Change in Clinical outcomes - stroke severity

    Stroke severity - NIHSS. Scale from 0-42. Increased number means increase in stroke severity.

    Time frame: Pre and post 2 week intervention

  8. Change in Clinical outcomes - tube status

    Feeding tube status

    Time frame: Pre and post 2 week intervention and at 90 days.

  9. Change in Clinical outcomes - mortality

    Mortality

    Time frame: Pre and post 2 week intervention and at 90 days.

  10. Change in Clinical outcomes - pneumonia

    Presence of pneumonia

    Time frame: Pre and post 2 week intervention and at 90 days.

06

Study locations

1 site
  • Royal Derby Hospital
    Derby, Derbyshire DE22 3NE, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03499574
Lead sponsor
University of Nottingham
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Jan 26, 2018
Primary completion
Mar 31, 2020
Completion
May 31, 2020
Last update
Oct 29, 2020

Study contacts

Timothy England, PhD
principal investigator · University of Nottingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion